Efficacy and safety of tisagenlecleucel in adult japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 elara trial

HIGHLIGHTS

• who: Noriko Fukuhara from the Department of Hematology, Tohoku University Hospital, u2011, Seiryou2011cho, Sendai, u20118574, Japan have published the research work: Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial, in the Journal: (JOURNAL) of March/29,/2021
• what: The authors report the efficacy safety and cellular kinetics of in a subgroup of Japanese patients with r/r FL from ELARA.

SUMMARY

Although chemo-immunotherapy 4 has improved the survival outcomes (median overall survival: ~ 20 years) in patients . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.